Open an account

MetaVia

MTVA · NASDAQ

$1.29+$0.06 (+4.88%)TodayMarket closed ·
Prev close $1.23

About MTVA

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Employees
8
Headquarters
Cambridge, Massachusetts
Listed
Aug 5, 2016
Sector
Health Care
Industry
Biotechnology
Website
metaviatx.com

MTVA key statistics

Market cap
8.50M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
58.24K
Volume
14.63K
Open price
$1.26
High today
$1.32
Low today
$1.20
52 Week high
$14.85
52 Week low
$0.9661

MetaVia (MTVA) at a glance

As of Oct 20, 2026, MetaVia (MTVA) shares are priced at $1.29, giving the company a market cap of 8.50M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.20 and $1.32. The current price is 7.5% above the day's low and 2.3% below its high.

Volume so far is 14.63K shares, below the average of 58.24K shares a day.

Over the past year MetaVia has ranged from $0.9661 to $14.85, and now sits 2% of the way up that range.

MetaVia met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.90 per share against an estimate of -$0.8364.

The average analyst price target is $19.72, 1428.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $19.72
Low
$8.08
Now
$1.29
High
$31.50

MTVA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 36.2% on average.

  1. Q3 FY24: reported -$6.05 per share against an estimate of -$8.19
  2. Q4 FY24: reported -$5.54 per share against an estimate of -$7.60
  3. Q1 FY25: reported -$3.96 per share against an estimate of -$6.76
  4. Q2 FY25: reported -$2.86 per share against an estimate of -$3.48
  5. Q3 FY25: reported -$1.54 per share against an estimate of -$2.49
  6. Q4 FY25: reported -$0.42 per share against an estimate of -$1.27
  7. Q1 FY26: reported -$0.79 per share against an estimate of -$0.7582
  8. Q2 FY26: reported -$0.90 per share against an estimate of -$0.8364

MTVA news

  • Press releasePRNewswire

    MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

  • Press releasePRNewswire

    MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

  • Press releasePRNewswire

    MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • Press releasePRNewswire

    MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

  • Press releasePRNewswire

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

  • Press releasePRNewswire

    MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

  • Press releasePRNewswire

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

  • Press releasePRNewswire

    MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

Similar companies

Companies in the same industry as MetaVia

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.